<DOC>
	<DOC>NCT02518971</DOC>
	<brief_summary>The study aims to evaluate the efficacy of prophylactic tamsulosin in reducing the incidence of postoperative urinary retention in primary total knee and hip arthroplasty patients.</brief_summary>
	<brief_title>Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients</brief_title>
	<detailed_description>Prophylactic administration of tamsulosin will be compared to a placebo to evaluate the effectiveness in reducing the incidence of postoperative urinary retention in total hip and knee arthroplasty patients.</detailed_description>
	<mesh_term>Urinary Retention</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Men age 35 or older Primary total hip and knee arthroplasty patients (general, spinal, or epidural anesthesia No current use (&gt;1 month) of alphablockers Community ambulator Adequate organ and marrow function as defined below: leucocytes at least 3,000/µL, absolute neutrophil count at least 1,500/µL, platelets at least 100,000/µL, creatinine within normal institutional limits Ability to understand, and the willingness to sign, a written informed consent History of radical prostatectomy Receiving any other investigational agents Revision hip and knee arthroplasty patients Severe liver or kidney disease Taking strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir/ritonavir, lopinavir, or conivaptan) Being on alphablockers (alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, phenoxybenzamine, or silodosin) Being of 5alpha reductase inhibitors (finasteride, dutasteride) History of allergy or sensitivity to tamsulosin or other alphablockers (alfuzosin, doxazosin, prazosin, terazosin, or phenoxybenzamine) Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Taking Sildenafil,Tadalafil, or Vardenafil</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>